Literature DB >> 9683297

Restricted expression of oncofetal fibronectin mRNA in thyroid papillary and anaplastic carcinoma: an in situ hybridization study.

T Takano1, F Matsuzuka, A Miyauchi, T Yokozawa, G Liu, S Morita, K Kuma, N Amino.   

Abstract

Restricted expression of oncofetal fibronectin mRNA in the tissues of thyroid papillary and anaplastic carcinoma has recently been shown by both Northern blot analysis and reverse transcriptase polymerase chain reaction (RT-PCR). Oncofetal fibronectin mRNA can be a target of gene diagnosis and targeted gene therapy, provided it is expressed in all cancer cells in the tissues. To investigate this criterion in thyroid cancer tissues, we measured their expression of oncofetal fibronectin mRNA using in situ hybridization. An abundant expression of oncofetal fibronectin mRNA was found in all the observed cancer cells of six papillary carcinomas and an anaplastic carcinoma, but not in the tissues of normal thyroid, Graves' disease, adenomatous goitre, follicular adenoma, follicular carcinoma or medullary carcinoma. This result encourages us to establish gene diagnosis of thyroid papillary and anaplastic carcinomas by detecting oncofetal fibronectin mRNA in biopsies.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9683297      PMCID: PMC2062902          DOI: 10.1038/bjc.1998.468

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  12 in total

1.  Isolation of a major cell surface glycoprotein from fibroblasts.

Authors:  K M Yamada; J A Weston
Journal:  Proc Natl Acad Sci U S A       Date:  1974-09       Impact factor: 11.205

2.  The WHO histological classification of thyroid tumors: a commentary on the second edition.

Authors:  C Hedinger; E D Williams; L H Sobin
Journal:  Cancer       Date:  1989-03-01       Impact factor: 6.860

3.  Distribution of oncofetal fibronectin in human mammary tumors: immunofluorescence study on histological sections.

Authors:  B Loridon-Rosa; P Vielh; H Matsuura; H Clausen; C Cuadrado; P Burtin
Journal:  Cancer Res       Date:  1990-03-01       Impact factor: 12.701

4.  Immunohistochemical expression of oncofetal fibronectin in benign and malignant lesions of the stomach.

Authors:  L David; U Mandel; H Clausen; M Sobrinho-Simões
Journal:  Eur J Cancer       Date:  1993       Impact factor: 9.162

5.  Detection of CD44 variants in fine needle aspiration biopsies of thyroid tumor by RT-PCR.

Authors:  T Takano; H Sumizaki; N Amino
Journal:  J Exp Clin Cancer Res       Date:  1997-09

6.  Follicular variant of papillary thyroid carcinoma. A clinicopathologic study.

Authors:  E T Tielens; S I Sherman; R H Hruban; P W Ladenson
Journal:  Cancer       Date:  1994-01-15       Impact factor: 6.860

7.  The oncofetal domain of fibronectin defined by monoclonal antibody FDC-6: its presence in fibronectins from fetal and tumor tissues and its absence in those from normal adult tissues and plasma.

Authors:  H Matsuura; S Hakomori
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

8.  Localization of oncofetal and normal fibronectin in colorectal cancer. Correlation with histologic grade, liver metastasis, and prognosis.

Authors:  H Inufusa; M Nakamura; T Adachi; Y Nakatani; K Shindo; M Yasutomi; H Matsuura
Journal:  Cancer       Date:  1995-06-15       Impact factor: 6.860

9.  Growth activity in hyperplastic and neoplastic human thyroid determined by an immunohistochemical staining procedure using monoclonal antibody MIB-1.

Authors:  R Katoh; C E Bray; K Suzuki; A Komiyama; A Hemmi; A Kawaoi; T Oyama; T Sugai; S Sasou
Journal:  Hum Pathol       Date:  1995-02       Impact factor: 3.466

10.  Primary structure of human fibronectin: differential splicing may generate at least 10 polypeptides from a single gene.

Authors:  A R Kornblihtt; K Umezawa; K Vibe-Pedersen; F E Baralle
Journal:  EMBO J       Date:  1985-07       Impact factor: 11.598

View more
  4 in total

1.  Analysis of splice variants of the fibronectin gene in thyroid carcinomas by reverse transcription-polymerase chain reaction: increased expression of oncofetal fibronectin mRNA in papillary carcinomas is not caused by the alternation in splicing.

Authors:  T Takano; F Matsuzuka; G Liu; A Miyauchi; T Yokozawa; K Kuma; N Amino
Journal:  J Endocrinol Invest       Date:  1999-01       Impact factor: 4.256

Review 2.  Molecular diagnostic tests in the diagnosis and management of thyroid carcinoma.

Authors:  M D Ringel
Journal:  Rev Endocr Metab Disord       Date:  2000-04       Impact factor: 6.514

3.  A multi-gene approach to differentiate papillary thyroid carcinoma from benign lesions: gene selection using support vector machines with bootstrapping.

Authors:  Krzysztof Fujarewicz; Michal Jarzab; Markus Eszlinger; Knut Krohn; Ralf Paschke; Małgorzata Oczko-Wojciechowska; Małgorzata Wiench; Aleksandra Kukulska; Barbara Jarzab; Andrzej Swierniak
Journal:  Endocr Relat Cancer       Date:  2007-09       Impact factor: 5.678

4.  High-throughput differential screening of mRNAs by serial analysis of gene expression: decreased expression of trefoil factor 3 mRNA in thyroid follicular carcinomas.

Authors:  T Takano; A Miyauchi; H Yoshida; K Kuma; N Amino
Journal:  Br J Cancer       Date:  2004-04-19       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.